Search clinical trials for: GVHD prophylaxis

Total 2864 results

Siriraj Hospital

Not yet recruiting

The Comparison the CMV Infection and Reactivation After Allogeneic Hematopoietic Stem Cell Transplantation Between Standard Regimen, Methotrexate Plus Cyclosporin A, and Post-transplant Cyclophosphamide-based Regimen (CMV)

CMV Infection or Reactivation After Allogenic HSCT
Wang Xin

Not yet recruiting

Prophylaxis of Graft-versus-host Disease With Anti-CD25 Antibody in Patients Underwent HSCT

GVHD

China
Instituto Nacional de Cancer, Brazil

Not yet recruiting

PTCy and ATG for MSD and MUD Transplants

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Hodgkin Lymphoma | Acute Lymphoblastic Leukemia | Non-hodgkin Lymphoma
Peking University People's Hospital

Not yet recruiting

Sirolimus+Abatacept+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to Calcineurin Inhibitors

Myelodysplastic Syndromes | Acute Leukemia | Severe Aplastic Anemia
Nantes University Hospital

Not yet recruiting

Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation (CY-MET-RIC)

Hematologic Malignancy | Graft Versus Host Disease
Federal Research Institute of Pediatric Hematology...

Recruiting

PTCy and and Ruxolitinib for GVHD Prophylaxis After HSCT With Thymoglobulin in Conditioning Regimen in Patients With Inborn Errors of Immunity

Inborn Errors of Immunity

Russian Federation
Assistance Publique - Hôpitaux de Paris

Not yet recruiting

Phase III Study Comparing GVHD Prophylaxis With ATG-thymoglobulin to ATLG-grafalon in Elderly Patients With Acute Myeloid Leukemia or Myelodysplasic Syndrome and Receiving an Allogeneic Hematopoietic Stem Cell Transplantation With a 10/10 HLA Matched Unrelated Donor (OPTISAGE)

GVHD
Washington University School of Medicine
Incyte Corporation

Recruiting

Ruxolitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation

Graft Versus Host Disease | Graft Vs Host Disease | Graft-versus-host-disease

United States
Shanghai Jiao Tong University School of Medicine
Shanghai Clinical Research Center

Not yet recruiting

Comparison of Different Dose of Post-transplantation Cyclophosphamide as Graft Versus Host Disease Prophylaxis

GVHD

China
Center for International Blood and Marrow Transplant...
National Marrow Donor Program

Recruiting

HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis (OPTIMIZE)

Lymphoma | Acute Myeloid Leukemia | Myelodysplastic Syndromes | Myelofibrosis | Chronic Myelomonocytic Leukemia | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Chronic Myeloid Leukemia | Acute Leukemia | Myeloproliferative Neoplasm | Pro-Lymphocytic Leukemia

United States
Institute of Hematology & Blood Diseases Hospital

Not yet recruiting

Ruxolitinib as GVHD Prophylaxis in AA Patients

The Prophylactic Value of Ruxolitinib for aGVHD in HSCT Recipients of AA
Central Hospital, Nancy, France
Saint-Louis Hospital, Paris, France

Not yet recruiting

Wharton Jelly Mesenchymal Stromal Cells as GVHD Prophylaxis (HAPLO-GEL)

Graft Failure | GVHD,Acute | Allogeneic Disease
Medical College of Wisconsin

Recruiting

De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis

Graft-versus-host Disease

United States
St. Jude Children's Research Hospital

Recruiting

A Phase II Pediatric Study of a Graft-VS.-Host Disease (GVHD) Prophylaxis Regimen With no Calcineurin Inhibitors After Day +60 Post First Allogeneic Hematopoietic Cell Transplant for Hematological Malignancies

Hematologic Malignancy | Myeloid Malignancy

United States
The First Affiliated Hospital of Soochow University

Recruiting

GVHD Prophylaxis by Addition of CD20 Monoclonal Antibody to the Conditioning Regimen in SAA With Treatment of Allo-HSCT

Aplastic Anemia

China
University Hospital, Lille
Biotest

Recruiting

Efficacy and Safety of Cytotect®CP, Hyperimmune Anti-CMV IVIg as CMV Prophylaxis in Patients Developing Acute Grade II-IV GVHD After Allogeneic Hematopoietic Cell Transplantation. (CMV-GVHD)

Cytomegalovirus Infections

France
National Research Center for Hematology, Russia

Not yet recruiting

Comparison of PT-Cy at a Dose of 25 mg/kg/Day and PT-Cy at a Dose of 50 mg/kg/Day in GVHD Prophylaxis (CY25)

Hematologic Malignancy | Graft Versus Host Disease | Cyclophosphamide Adverse Reaction
DKMS gemeinnützige GmbH

Recruiting

GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG (GRAPPA)

AML | MDS | Peripheral Blood Stem Cell Transplantation | Graft Vs Host Disease | CMML | MDS/MPN

Germany
The First Affiliated Hospital of Soochow University
The First Affiliated Hospital with Nanjing Medical University; Shenzhen People... and other collaborators

Recruiting

Sitagliptin for Prevention of aGVHD After Alternative Donor Transplantation

Allogeneic Hematopoietic Stem Cell Transplantation | Acute-graft-versus-host Disease

China
Masonic Cancer Center, University of Minnesota

Recruiting

PTCy + Sirolimus/VIC-1911 as GVHD Prophylaxis in Myeloablative PBSC Transplantation

Lymphoma | Myelodysplastic Syndromes | Acute Leukemia | Myeloproliferative Neoplasm

United States
ExCellThera inc.
Memorial Sloan Kettering Cancer Center

Recruiting

US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies

Cord Blood Transplant | High Risk Myeloid Malignancies

United States
University of Sao Paulo General Hospital
Libbs Farmacêutica LTDA

Recruiting

GVHD Prophylaxis With Methotrexate in Haploidentical HCT Using Posttransplant Cyclophosphamide

Hematopoietic Neoplasm | Graft Vs Host Disease

Brazil
King Faisal Specialist Hospital & Research Center

Recruiting

Comparing Post-Transplant Cyclophosphamide as GVHD Prophylaxis to Standard of Care for Acute Leukemia Patients (PTCy-PMAT)

Acute Myeloid Leukemia (AML) in Remission | Acute Lymphoblastic Leukemia (ALL) in Complete Remission

Saudi Arabia
Universitätsklinikum Hamburg-Eppendorf
Clinical Trial Center North (CTC North GmbH & Co. KG); DKMS Stiftung Leben...

Recruiting

Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia

Myelodysplastic Syndromes | Acute Myeloid Leukemia in Remission | Acute Lymphoblastic Leukemia in Remission

Germany, Spain, Italy, Austria, Czechia, Finland, Russian Federation
Nanfang Hospital of Southern Medical University

Recruiting

ATG in HLA-matched Sibling HSCT as GVHD Prophylaxis

Hematopoietic Stem Cell Transplantation

China
National Cancer Institute (NCI)

Recruiting

Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma

Immune System Diseases | Lymphoproliferative Disorders | Peripheral T-cell Lymphomas

United States
University of Liege
Belgian Hematological Society

Recruiting

Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning (HLA)

Myelodysplastic Syndromes | Multiple Myeloma | Hodgkin Lymphoma | Non Hodgkin Lymphoma | Myeloproliferative Disorder | Chronic Lymphoid Leukemia | Acute Myeloid Leukemia in Remission | Myeloproliferative Syndrome | Chronic Myeloid Leukemia in Remission | Acute Lymphoid Leukemia in Remission

Belgium
National Cancer Institute (NCI)

Recruiting

Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation

Immune System Diseases | Lymphoproliferative Disorders | Common Variable Immunodeficiency | Primary T-cell Immunodeficiency Disorders | Autoimmune Lymphoproliferative

United States
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis

Paroxysmal Nocturnal Hemoglobinuria (PNH) | Severe Aplastic Anemia (SAA) | Hypo-Plastic Myelodysplastic Syndrome (MDS)

United States
AHS Cancer Control Alberta

Recruiting

HIgh Dose Thymoglobulin Instead of Cyclosporine With a Low Dose of Thymoglobulin for GVHD Prophylaxis (ATG2017)

Relapse | Graft-versus-host-disease

Canada
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Institutes of Health (NIH)

Recruiting

Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation

Diffuse Large B-Cell Lymphoma | Acute Myeloid Leukemia | Recurrent Hodgkin Lymphoma | Acute Lymphoblastic Leukemia | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Myelodysplastic Syndrome | Recurrent Small Lymphocytic Lymphoma | Blastic Plasmacytoid Dendritic Cell Neoplasm | Prolymphocytic Leukemia and other conditions

United States
Washington University School of Medicine

Recruiting

Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders

Hemoglobinopathies | Bone Marrow Failure Syndromes | Metabolic Disorders | Non-malignant Disorders | Severe Sickle Cell Disease | Immunologic Disorders

United States
National Cancer Institute (NCI)

Recruiting

Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies

Immune System Diseases | Lymphoproliferative Disorders | Common Variable Immunodeficiency | Primary T-cell Immunodeficiency Disorders | Autoimmune Lymphoproliferative

United States
University Hospital, Angers

Recruiting

Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR (BIG-1)

Acute Myeloid Leukemia (AML)

France
National Cancer Institute (NCI)

Suspended

Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies in People Living With HIV

HIV | Hematologic Malignancies

United States
University of Liege
University Hospital, Gasthuisberg; University Hospital, Ghent; University Hospital... and other collaborators

Active, not recruiting

Minitransplants With HLA-matched Donors : Comparison Between 2 GVHD Prophylaxis Regimens

Hematological Malignancies | Graft-Versus-Host Disease

Belgium
Dimitrios Tzachanis, MD PhD
Bristol-Myers Squibb

Active, not recruiting

Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation

Hematologic Neoplasms | GVHD

United States
Medical College of Wisconsin
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaborators

Completed

TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801) (1703/1801)

Lymphoma | Acute Leukemia | Myelodysplasia | Chronic Myelogenous Leukemia (CML)

United States
Fundación Pública Andaluza para la gestión de la...

Active, not recruiting

Ixazomib in the Prophylaxis of Chronic Graft-versus-host Disease.

Multiple Myeloma | Hematopoietic Stem Cell Transplantation

Spain
Edwin Horwitz
Ossium Health, Inc.

Suspended

Interferon γ-Primed Mesenchymal Stromal Cells as Prophylaxis for Acute Graft v Host Disease

Myelodysplastic Syndromes | Acute Leukemia

United States
University of Nebraska
National Cancer Institute (NCI)

Terminated

Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer

Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent... and other conditions

United States
Spectrum Health Hospitals
Millennium Pharmaceuticals, Inc.

Completed

Post-Transplant Bortezomib and High Dose Cyclophosphamide as Graft-Versus-Host Disease (GVHD) Prophylaxis

Hematological Malignancy

United States
Mehdi Hamadani
West Virginia University

Completed

Atorvastatin as GVHD Prophylaxis for Allogeneic Hematopoietic Cell Transplantation

Graft vs Host Disease

United States
Masonic Cancer Center, University of Minnesota

Active, not recruiting

Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT

Hematologic Malignancies

United States
Boston Children's Hospital
FDA Office of Orphan Products Development

Active, not recruiting

Abatacept as GVHD Prophylaxis Phase 2

Graft vs Host Disease | Malignancy

United States, Canada
Medical College of Wisconsin
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute...

Completed

PROACTIVE: Preventing Acute/Chronic GVHD With TocIlizumab Combined With GVHD Prophylaxis Post allogEneic Transplant

Hematologic Malignancy

United States
Gruppo Italiano Trapianto di Midollo Osseo

Completed

Post Transplant High-Dose Cy as GvHD Prophylaxis in 1 HLA Mismatched Unrelated HSCT for Myeloid Malignancies (GITMO-PHYLOS)

Myeloid Malignancies

Italy
National Heart, Lung, and Blood Institute (NHLBI)
National Cancer Institute (NCI); Blood and Marrow Transplant Clinical Trials...

Completed

Calcineurin Inhibitor-Free Interventions BMT CTN 1301 for Prevention of Graft-versus-Host Disease (BMT CTN 1301)

Acute Leukemia | Myelodysplasia

United States
Virginia Commonwealth University
Massey Cancer Center

Completed

Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma | Hodgkin's Lymphoma | Recurrent Hodgkin Lymphoma | Chronic Lymphocytic Leukemia | Non Hodgkin Lymphoma | Acute Lymphocytic Leukemia | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | Recurrent Non-Hodgkin Lymphoma | Recurrent Plasma... and other conditions

United States
Medical College of Wisconsin
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaborators

Terminated

Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202)

Follicular Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma

United States

Search clinical trials for: GVHD prophylaxis

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Senegal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations